Docebo's recent performance showcases its robust growth trajectory, with earnings surging 130.2% over the past year and projected to grow by 34.1% annually for the next three years. The company reported Q2 2024 sales of $53.05 million, up from $43.59 million a year ago, illustrating strong revenue momentum at a forecasted annual rate of 14.7%. Additionally, Docebo's R&D expenses reflect its commitment to innovation; it invested $10.3 million in Q2 2024 alone, ensuring continuous enhancement of its SaaS learning platform for an expanding client base.

• Unlock comprehensive insights into our analysis of Docebo stock in this health report.

• Examine Docebo's past performance report to understand how it has performed in the past.

Vitalhub

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Vitalhub Corp., along with its subsidiaries, offers technology solutions for health and human service providers across Canada, the United States, the United Kingdom, Australia, Western Asia, and other international markets with a market cap of CA$405.81 million.

Operations: Vitalhub generates revenue primarily through its healthcare software segment, which accounted for CA$58.32 million. The company operates in multiple international markets, including Canada, the United States, the United Kingdom, Australia, and Western Asia.

Vitalhub's recent performance highlights its dynamic growth within the tech sector, with revenue for Q2 2024 reaching CAD 16.24 million, up from CAD 13.09 million a year ago. Despite a net loss of CAD 0.34 million this quarter compared to net income of CAD 0.62 million last year, the company's earnings are projected to grow at an impressive annual rate of 65.9%. Notably, Vitalhub's R&D expenses underscore its innovation commitment; it invested significantly in developing new solutions tailored for healthcare clients, ensuring future scalability and market relevance.

• Click to explore a detailed breakdown of our findings in Vitalhub's health report.

• Gain insights into Vitalhub's historical performance by reviewing our past performance report.

Next Steps

• Click through to start exploring the rest of the 20 TSX High Growth Tech and AI Stocks now.

• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.

• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include TSX:CGX TSX:DCBO and TSX:VHI.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]